Growth hormone releasing peptides (GHRPs) – classification, mechanism of action and scientific evidence

Growth hormone releasing peptides, abbreviated as GHRP (English). growth hormone-releasing peptides), is a group of compounds rather than a single substance. In the traditional pharmacological sense, the term includes synthetic peptides such as GHRP-2 and GHRP-6 that stimulate the secretion of growth hormone through the receptor system associated with the secretion of this hormone. A 1996 study on the cloning of the receptor helped characterize this signaling pathway, while the discovery of grelin in 1999 enabled the identification of its natural ligand.[1][2]

Studies confirm the biological activity of GHRP, including measurable growth hormone secretion responses in humans. However, this does not mean that these compounds reliably increase muscle mass, accelerate regeneration, improve sleep, or prolong life. The article focuses on the chemical identity and scientific evidence, with particular emphasis on GHRP-2 and GHRP-6, rather than treating the entire group as a standardized treatment method.

What are growth hormone releasing peptides? Names, synonyms, and identity

Naming is important because scientific publications sometimes use functional terms where the reader expects the name of a specific chemical compound. A study describing the response of growth hormone to a substance that stimulates its secretion may concern a peptide, a nonpeptide compound, or an intervention involving several hormonal pathways. The title and abstract of the publication itself do not always allow determining which material was given to the participants. Identifying the actual substance prevents unwarranted attribution of GHRP-2 or GHRP-6 results derived from the broader literature on growth hormone secretion stimulators.

In a scientific database, names should be associated with a specific chemical identity and, if available, the exact formulation used in the publication. Synonyms help to find older studies, but do not replace confirmation of the substance analyzed by the researchers. This is especially important when publications simultaneously discuss historical development codes, diagnostic preparations, and synthetic analogues.

The term „growth hormone releasing peptides” describes a class of substances. GHRP-2 and GHRP-6 are its distinct representatives with different structures. GHRP-2 is also known as prallmorelin and KP-102. Japanese regulatory documents identify the hydrochloride form used in the diagnostic preparation.[3]

The term „substance that stimulates the secretion of growth hormone” (growth hormone secretagogue) refers to a broader functional category that includes compounds that stimulate the secretion of growth hormone. It should not be automatically identified with the name peptide.

Similarly, the growth hormone-releasing hormone, referred to by the acronym GHRH, is not another name for GHRP. Both receptor systems are distinct, although their actions may complement each other. [1] [4]

Greline also requires proper differentiation. It is an endogenous peptide hormone associated with the same receptor system, but it does not constitute a synonym for GHRP-2 or GHRP-6. Its discovery clarified an important element of the biology of this system, without making synthetic analogs identical to the natural hormone. [2]

The identification verification should therefore start with the full name of the compound, and not with an advertising term such as „GH peptide”. Then, the exact chemical form, formulation, and study to which the source refers should be determined. The name of the class itself does not provide this information.

How are growth hormone releasing peptides classified? Peptide, protein, mixture or other substance?

The structural and pharmacological classification answers two separate questions. A peptide is identified based on its amino acid-based structure, while a substance that stimulates hormone secretion is defined by its biological action.

Classical GHRPs meet both criteria, however, a broader group of substances that stimulate growth hormone secretion may include compounds devoid of a peptide chain. This explains why the common hormonal effect is not sufficient to establish a chemical classification.

GHRP should also be distinguished from hormone replacement therapy. The administered substance that stimulates hormone secretion acts on the regulatory mechanisms of the body, and the measured response may depend on the initial functioning of the hormonal system and the conditions of the experiment.

Direct administration of the hormone is another intervention. Similar changes in blood tests do not indicate equivalence of further biological effects or risk.

The classic GHRP discussed in the article are synthetic peptides that exhibit activity that stimulates the secretion of growth hormone. They are not growth hormone itself or mixtures of growth hormone and amino acids.

Stimulating the secretion of a hormone by the functioning hormonal system is biologically different from administering the measured hormone directly.

The classification should also not be based on marketing promises. Terms such as „muscle peptide” or „anti-aging peptide” do not confirm the chemical identity or proven clinical indication.

The classification should be based on the structure of the compound and confirmed pharmacology. Claims of benefits require separate evidence.

The structure and composition of growth hormone-releasing peptides – what has been established?

The length of the six amino acid residues in GHRP-2 and GHRP-6 is only one element of their identity. The order of the residues, the stereochemistry, and the chemical structure of the chain ends also play a role.

The D-amino acid is not merely an alternative representation of the L counterpart; it differs in its spatial arrangement of atoms, which can affect the molecule's interaction with biological targets.

Replacing the non-standard amino acid residue or omitting the final modification leads to a change in the chemical substance in question.

Analytic documentation requires similar caution. The percent yield of chromatographic analysis may describe the proportion of detected material under specific conditions, rather than providing comprehensive confirmation of sequence, stereochemistry, anti-ions, microbiological quality, or suitability for a specific route of administration.

The identity of the active peptide and the quality of the finished medicinal product are related to each other, but they are separate issues. None of these characteristics can be determined solely by the trade name.

When comparing the studies, it should be noted whether the authors specified the form of the salt, the aqueous preparation, or another pharmaceutical form.

These details may be relevant for reproducibility and interpretation, but they do not prove that the uncharacterized preparation from another supplier behaves the same as the material used in the publication.

The similarity of the names does not constitute a basis for assuming clinical interchangeability.

GHRP-2 and GHRP-6 are peptides composed of six amino acid residues, but they differ in sequence.

The sequence of GHRP-6 is described in the following record:

His–D-Trp–Ala–Trp–D-Phe–Lys–NH₂

The D designations indicate stereochemistry, whereas the final NH₂ indicates amidation of the chain end. These are elements of chemical identity, not optional designations.[5]

In the case of GHRP-2, the Japanese evaluation documentation indicates the sequence corresponding to:

D-Ala–D-2-naphthylalanine–Ala–Trp–D-Phe–Lys–NH₂

The documentation also identifies dichlorovodoric acid salt.

The non-standard rest of the naphthylalanine has particular significance in distinguishing this substance from ordinary peptides derived from food. [3]

The sequence itself does not constitute a complete specification of the finished product.

The salt content, water content, peptide content, impurities, excipients, and stability can all affect the comparability of materials.

The chromatographic purity result is also not equivalent to confirming all structural details or pharmaceutical suitability.

There is no single summary formula or single molecular mass that describes the entire class of GHRPs.

These parameters refer to a specific molecule and its chemical form. Providing a single formula under the general heading „growth hormone-releasing peptides” would incorrectly represent the entire category as a single substance.

Research on growth hormone-releasing peptides – evidence in humans, animals and in the laboratory

The evidence base is best analyzed as a collection of separate research questions, rather than a single test of whether GHRPs work.

Exploratory experiments concern receptor biology. Short-term studies in humans assess hormonal responses and appetite. Diagnostic studies verify whether the induced hormonal response helps classify patients.

Pediatric studies analyze the growth of selected children. Models of damage in animals, however, allow determining whether certain biological changes occur under experimental conditions.

Each result is relevant within the limits of its own project, but the evaluated final points are not interchangeable.

The size of the study and the duration of the study are particularly important.

A short-term hormonal experiment can detect a clear change in hormone levels in a relatively small number of participants.

However, it is not designed to estimate rare adverse events or to show that the change persists over the years.

The diagnostic study may involve more participants, but it still does not answer the question of whether repeated exposure improves physical fitness.

Interpreting the number of participants without considering the purpose of the study can lead to an incorrect assessment of the strength of the evidence.

Hormonal responses in humans

The hormonal response should be described taking into account the experimental conditions.

The initial hormone concentrations, the time of sample collection, the specific peptide, and the presence of endogenous regulatory signals all influence the significance of the measured maximum concentration.

The antagonist experiment conducted on nine men is particularly important because it examined the involvement of endogenous GHRH, rather than merely recording the response after the substance was administered.

The result confirms the physiological interaction of the systems, but it does not mean that both receptor pathways are identical.

Additional observations regarding prolactin, ACTH and cortisol are also important.

They indicate that the term „releasing growth hormone” does not provide a complete description of the possible hormonal effects.

The publication presenting changes in several hormones should not be reduced to a single beneficial biomarker, especially when assessing selectivity and long-term use.

Studies in humans confirm that these peptides can stimulate the secretion of growth hormone.

In a 1998 mechanistic study involving nine healthy men, it was found that blocking endogenous GHRH significantly reduced the response to GHRP-6.

This result indicates the interaction of regulatory systems, rather than complete independence from proper hypothalamic signaling.[4]

Changes may also affect other hormones.

In a small comparative study from 1997 involving GHRP-2 and hexarelines, changes in prolactin, ACTH, and cortisol levels as well as growth hormone were noted.[6]

Therefore, the term „growth-hormone releaser” should not be interpreted as a guarantee of complete hormonal specificity.

Diagnostic tests

Diagnostic effectiveness depends on the question that the test is intended to answer.

Researchers compare the results with the reference assessment and analyze whether they allow them to distinguish between the appropriate groups of patients.

Sensitivity, specificity, reproducibility, and the influence of factors such as age and the amount of adipose tissue are therefore more important than claims regarding improvement in physical performance.

The test can be useful even if it causes short-term stimulation that is not intended to maintain a long-lasting physiological effect.

The regulatory approval of a diagnostic product also has a narrower scope than the approval of an entire chemical class for chronic treatment.

The Japanese documentation concerns a specific product containing praltmorelin and a specific indication.

It does not support the inclusion of GHRP-6, undefined combinations, or unrelated indications in Poland or other countries.

Any information about the regulatory status should indicate the country and the product.

A 2007 study evaluated GHRP-2 in 77 healthy participants and 58 patients with growth hormone deficiency, determined based on comparative studies used in the protocol.

The ability of the test to distinguish between groups and its reproducibility were analyzed, taking into account some influence of age and amount of adipose tissue.[7]

These are important evidence from human studies, but they relate to diagnostics.

A test that helps characterize the secretory capacity of the hormonal system does not automatically become a chronic therapy that increases muscle strength or reverses the aging process.

The documentation from the Japanese PMDA describes the development and evaluation of the approval of pramiracetam for the diagnosis of growth hormone deficiency. This specific context should not be generalized to all countries or applications.[3]

Studies on appetite

The reported difference of 36% refers to the amount of food consumed during a specific experimental meal.

It does not mean a change in body weight of 36% or does not constitute a long-term appetite forecast.

The study included only seven lean men, therefore the population and the observation period were very limited.

Appetite and food intake may also depend on circumstances, which makes the study provide information about an acute physiological response, but does not resolve long-term nutritional or metabolic outcomes.

This result also prevents the assumption that all substances that stimulate the secretion of growth hormone cause one desired direction of changes in body weight.

A peptide that increases food intake under certain conditions should not be described as a proven weight-loss agent just because it appears in metabolic studies.

In a controlled crossover study from 2005 involving seven lean, healthy men, short-term exposure to GHRP-2 increased food intake during a buffet meal by approximately 36% compared to a saline solution.[8]

The result confirms the acute response associated with eating the food under the experimental conditions.

It does not demonstrate a sustained improvement in nutritional status nor justifies the classification of the compound as a substance with a natural effect on weight reduction.

Long-term pediatric studies

The rate of growth is an important pediatric measure, but its interpretation depends on the initial growth pattern, maturation, underlying disease, and available comparison.

The study involving 15 children and the study of six children with growth hormone deficiency provide observations over longer periods than short hormone experiments.

However, small groups and design constraints reduce the certainty of the causal inference.

The fact that only six children in the first study continued to participate in the extended follow-up period further limits the conclusions regarding further results.

In the second study, an increase in growth rate was observed without simultaneous increases in IGF-I or IGFBP-3.

This suggests that hormone markers do not always change in the same way.

It would not be appropriate to draw conclusions based on these pediatric results regarding improving adult muscle strength, injury recovery, or longevity.

Such claims require studies that directly measure these results.

In a 1997 study, 15 children with low birth weight were observed for six months, and six continued to participate for 18–24 months.

An increase in the growth rate has been observed, but a small group and a limited comparative project reduce the certainty of the conclusions.

The results cannot be transferred to claims regarding bodybuilding or the prevention of aging in adults.[9]

An eight-month study involving six children with growth hormone deficiency also analyzed repeated exposure to GHRP-2.

During treatment, the growth rate increased, while the concentrations of IGF-I and IGFBP-3 did not increase. [10]

These observations show why the growth hormone response, further biomarkers, and clinical growth outcomes should be presented separately.

Animal studies and laboratory tests

Preclinical studies allow the analysis of tissues, biological pathways, and controlled models of damage that cannot be reproduced in the same way in humans.

The study of lung damage in mice from 2026 belongs to this category.

Changes in inflammatory markers or histological results may suggest hypotheses for further study, but the species, the mode of injury, and the experimental conditions limit the direct transfer of the results to the treatment of respiratory diseases in humans.

The same principle applies to receptor experiments.

Demonstrating that a compound activates a specific molecular target is an important mechanistic result, but it is only one step between exposure and a clinically useful effect.

Separate studies are needed to assess the actual benefits and adverse effects in the target population.

Receptor experiments and primary studies on grelin help to explain the functioning of the system that regulates the secretion of growth hormone.

They constitute a mechanistic basis, but not a complete assessment of the benefit-risk ratio in humans.[1][2]

The research also goes beyond the secretion of hormones alone.

A 2026 publication analyzed GHRP-6 in mouse models of acute lung injury and subsequent fibrosis.

Changes in inflammatory, physiological, and tissue parameters were noted.[11]

These are preclinical evidence obtained in models of artificially induced injury.

They do not confirm the effectiveness of treatment for respiratory diseases in humans or the overall improvement of regeneration.

Modified derivatives and antagonists also require separate evaluation.

The publication regarding the truncated analog of GHRP-6 may analyze a molecule with a different pharmacological role.

The similarity in the name does not mean that the results constitute direct evidence regarding unmodified GHRP-6.

The mechanisms of action studied for growth hormone releasing peptides

The distinction between GHS-R1a and the GHRH receptor provides a useful basis for interpreting partially overlapping effects.

Both systems are involved in the regulation of growth hormone secretion, but they are not the same molecular target.

The interactions observed in human antagonist experiments therefore confirm the physiological coordination rather than the interchangeability of the two compounds or the proven therapeutic role of their combination.

The discovery of the grelina also highlights the difference between endogenous signaling and the design of synthetic substances.

Naturally produced acylated peptide can serve as a reference point for receptor biology, whereas a shorter synthetic peptide can activate the same receptor with a different molecular structure.

The resulting hormonal response should be measured, and not assumed based on common receptor terminology.

The secretion of hormones is also a dynamic process.

The single measured maximum concentration does not describe all subsequent hormonal responses, long-term tissue effects, or clinical outcomes.

Studies of appetite, other pituitary hormones, and other markers provide additional context, but do not replace the direct assessment of the proposed clinical benefit.

The main hormonal mechanism involves the activation of the receptor for growth hormone-stimulating substances, most commonly referred to as the GHS-R1a or the growth hormone receptor.

This is a receptor system associated with the G protein, which is involved in controlling the secretion of growth hormone at the pituitary and hypothalamus levels.[1]

The original study on grelin identified an endogenous ligand composed of 28 amino acids whose acylation was essential for the activity analyzed, which promoted the secretion of growth hormone. [2]

This result explains why receptor biology cannot be predicted solely based on the length of the peptide or the presence of amino acids in the preparation.

Experiments with GHRP-6 using a GHRH antagonist show that distinct receptors may be involved in the same physiological response.[4]

The specificity of the receptors does not mean that the hormone systems operate independently.

It also does not mean that combining substances provides a proven clinical advantage. A higher peak concentration of the hormone is not automatically a better health outcome.

Answers regarding appetite and hormones other than GH further complicate presenting the effect as a single benefit.

The studies justify questions about what changed when the change occurred and whether it was desired in the analyzed population.

Biological activity can be relevant both for potential benefits and for possible adverse effects.

Limitations of scientific evidence regarding growth hormone-releasing peptides

An additional limitation is the uneven amount of evidence regarding individual representatives of the class.

GHRP-2 has a history of diagnostic studies and regulatory assessments that cannot be automatically transferred to GHRP-6.

Similarly, the results regarding the modified analog, antagonist, or combination intervention should remain attributed to that intervention exactly.

Combining the results just because the names look similar would artificially increase the apparent amount of evidence for individual molecules.

A transparent summary should provide the number of participants, the studied population, a comparator, the observation period, and the primary endpoint, if this information is available.

It should also indicate whether the result was measured directly or inferred based on a biomarker.

If the available source does not present a specific result, it is better to ignore it than to invent the magnitude of the effect or assume that a favorable hormonal response means a health benefit.

Hormone measurements are not equivalent to clinical results

The clinical significance depends on what actually improved.

Changes in the concentration of growth hormone in the blood can confirm the effect of the peptide on the biological system.

The claim of improved muscle function, however, requires measurements of strength or physical fitness.

The claim of healing requires relevant results regarding injuries or regeneration.

The claim of longevity requires a completely different range of observations.

These differences are not solely terminological. They determine whether the evidence at all answers the question about the proposed benefit.

The increase in the concentration of growth hormone is a pharmacodynamic result.

Demonstrating stronger muscles, better physical fitness, faster wound healing, or longer survival requires studies that directly measure these effects.

Neither a short-term peak in hormone levels nor a change in a single downstream biomarker confirms all of these benefits.

The selected literature includes diagnostic studies, small physiological experiments, pediatric studies, and animal models.

Combining these publications into one large list of „benefits” blurs the differences between research questions.

The child's growth rate, the adult's food intake, and the mouse's tissue response should remain separate results.

Safety depends on the connection, route of administration and product

Safety signals should be presented with a degree of certainty based on the evidence.

Regulatory warning may indicate potential hazards, reported adverse events, or a lack of information.

These are not equivalent statements.

The reporting of a serious incident does not in itself prove that the relationship caused it.

At the same time, an unresolved causal relationship does not constitute a basis for ignoring the report.

The correct conclusion is that there remains uncertainty that requires further assessment.

The quality of peptides introduces additional issues beyond their pharmacological action.

Aggregation, impurities, and immunogenicity are issues related to the product that may depend on the manufacturing and formulation.

A short laboratory certificate does not independently resolve all of these issues.

The results obtained for the controlled clinical preparation also do not confirm the safety of the material sold under a similar name unrelated to it.

The US FDA lists potential safety concerns regarding prescription products containing GHRP-2 and GHRP-6, including aggregation, peptide-related impurities, and immunogenicity.

The agency also describes concerns regarding changes in blood glucose and cortisol levels with GHRP-6.

With regard to GHRP-2, the FDA indicates that there have been reported serious events in people exposed to this substance, clearly stating that a causal relationship has not been established.[12]

This information should not be ignored or turned into a claim that the peptide caused each reported event.

They indicate uncertainty and specific issues that require evaluation.

Small, short-term studies do not allow to reliably rule out rare or delayed adverse reactions.

Scope of evidence and possibility of its transfer

The review also does not consider the absence of a large study with a negative result as evidence of benefit.

If long-term controlled studies are not available, the correct statement is that the effect has not been adequately confirmed.

This applies to claims about improving the performance of healthy adults, sleep, preventing aging, and the widely understood regeneration of tissues.

Mechanistic and animal data may justify further studies, but they do not change the level of clinical evidence in humans.

One result regarding one GHRP does not automatically apply to another.

Approval of the diagnostic use does not mean approval of chronic treatment.

The formulation and route of administration also affect exposure.

The product described as intended solely for scientific research (for research use only, (RUO) does not obtain pharmaceutical quality or proven clinical efficacy solely because the publications describe the properties of the molecule contained in it.

Confirmation of specific long-term benefits would require larger, well-controlled studies with direct functional measurements, a systematic assessment of adverse events, and a validated intervention.

Current evidence justifies nuanced conclusions, rather than extreme statements that nothing is known or that the entire class has been clinically confirmed.

Frequently asked questions about growth hormone releasing peptides

1. Do growth hormone releasing peptides represent one defined substance?

No. The term identifies a class that includes distinct compounds such as GHRP-2 and GHRP-6. Their structures and evidence base are not identical. A credible scientific claim must indicate a specific compound and formulation, rather than treating the entire category as one drug. The class name is useful for organizing the literature, but the result should be attributed to the exact substance. Otherwise, observations regarding one sequence may seemingly confirm the action of another molecule with a different chemistry and research history.

2. What do the available studies on growth hormone-releasing peptides confirm?

They confirm the activity that stimulates the secretion of growth hormone, the diagnostic uses of certain preparations, and additional results characteristic of individual compounds. [7] However, they do not confirm all the claimed benefits regarding performance or anti-aging. The conclusion depends on whether the study measured the hormonal response, the diagnostic result, or the actual clinical effect. The most certain conclusions concern endpoints directly evaluated in individual publications. Human hormonal responses are confirmed, but many broader claims remain unexamined or insufficiently documented in controlled clinical trials.

3. Are GHRP-2 and GHRP-6 interchangeable?

No. They are different molecules, although both can stimulate the secretion of growth hormone. The sequence, exposure, and effects unrelated to GH are important when comparing them. A positive result regarding one compound does not confirm the efficacy, tolerance, or appropriate role of the other without direct evidence. Even closely related peptides can differ in the strength and selectivity of their effects on physiological pathways. Without proper comparison, they cannot be ranked for clinical usefulness based solely on their belonging to the same class.

4. Is GHRP-2 also called prallmorelin?

Yes. Pralmoreline is the name associated with GHRP-2, also developed under the designation KP-102. Japanese documentation specifies the hydrochloride salt form.[3] The salt form and the finished formulation remain relevant, therefore the recognition of the synonym does not imply equivalence of all products bearing this name. The Japanese diagnostic context is particularly important when interpreting the name pralmoreline. It refers to a defined product intended to assess the secretion of growth hormone, and not to a general approval of all applications related to GHRP.

5. Are GHRPs the same as growth hormone?

No. They stimulate the secretion of growth hormone rather than the hormone itself. Differentiation is important because the secretory response depends on the stimulated biological system. Evidence regarding hormone replacement therapy cannot be automatically transferred to substances that stimulate hormone secretion simply because both approaches target the same measured hormone. Secretagogues utilize the response of the hormonal system, whereas administering the hormone directly delivers it to the body. Their pharmacology, clinical questions, and safety require independent evaluation.

6. Are GHRP the same as GHRH?

No. These names describe different signaling substances and receptor pathways. However, studies of GHRP-6 in humans have shown an interaction with endogenous GHRH. [4] These systems are physiologically related, but their names, mechanisms, and scientific evidence should remain separate. The interaction of the pathways does not mean that they can be treated as a single mechanism. Studies involving both systems should indicate which endogenous receptor or signal was analyzed.

7. Is grelina identical to GHRP-6?

No. Grelin is an endogenous acetylated peptide of a different structure. The original identification study associated it with a receptor system that regulates the secretion of growth hormone. [2] The common receptor biology does not mean that the synthetic GHRP-6 is a naturally identical substitute for grelin or exhibits the same effects under all conditions. Grelin also performs physiological roles beyond the simplified description of growth hormone secretion. The common receptor target does not justify the assumption that the synthetic hexapeptide replicates all the effects of the natural hormone.

8. Does a higher peak of growth hormone concentration indicate an increase in muscle mass?

No. The maximum concentration of a hormone is not a measure of size or muscle strength. Training, nutrition, initial health status, exposure time, and other biological responses can influence the results. The claim of muscle growth requires direct, controlled evidence, not inference based on a short hormonal experiment. The transient hormonal response is a useful endpoint in pharmacodynamic terms, but it does not measure permanent changes in muscle tissue or physical fitness. Such results require separate controlled observation.

9. Can GHRP-2 affect appetite?

Yes. In a short-term study involving seven healthy men, an increased intake of food was observed compared to a saline solution. [8] This small experiment does not confirm a long-term change in body weight or nutritional benefits. It indicates an appetite-related effect under the examined conditions, however broader consequences require appropriate studies. The measured difference concerns one controlled meal and should not be transformed into a prediction of daily calorie intake or long-term body weight. The small number of participants and the narrow population further limit the possibility of generalization.

10. Do these peptides only affect growth hormone?

Not necessarily. Other hormone responses were also reported in the studies. Comparisons of GHRP-2 and hexarelines included changes in prolactin, ACTH, and cortisol. [6] Claims of total hormonal selectivity therefore require evidence for a specific compound and should not be based solely on the name of the class. The hormonal system involves interacting regulatory pathways, and the response may depend on the molecule and the experimental conditions. Reports should indicate each measured hormone, rather than assuming complete selectivity.

11. Does the diagnostic use prove the benefits of chronic treatment?

No. A diagnostic test serves to obtain information, whereas treatment must improve the appropriate clinical outcome. The GHRP-2 diagnostic study concerns the evaluation of secretory capacity. [7] Its usefulness does not confirm that repeated exposure yields benefits for healthy adults or individuals with unrelated conditions. The diagnostic study assesses whether the response allows for the differentiation of clinical groups. It does not demonstrate that repeated stimulation improves health or function over the long term.

12. Can the results regarding children's growth confirm the anti-aging effects in adults?

No. Linear growth in childhood and the aging processes in adults are different issues. Small pediatric studies included selected children and measured growth-related outcomes. [9] [10] They cannot confirm the prolongation of life in adults, improvement of regeneration, or physical fitness. Children with growth disorders and healthy adults have fundamentally different clinical endpoints. Transferring the results would require new studies rather than reinterpreting observations of growth rate.

13. Does the examination of damage in animals confirm the effectiveness of the treatment for humans?

No. It confirms the result obtained in the model analyzed. A recent study of GHRP-6 regarding lung damage was conducted on mice, not on patients. [11] Transferring the results to humans would require appropriate clinical studies, rather than treating tissue changes in an experimental model as proven therapeutic benefits. Animal results may help prioritize research and identify potential biological pathways. They do not confirm efficacy, safety, or appropriate use in humans without clinical studies.

14. Why are D-amino acids and chain-ending chemistry important?

They constitute part of the molecule’s identity and can influence its biological behavior. The published sequence of GHRP-6 clearly contains D residues and an amidated chain end. [5] Omission of these details can cause structurally different materials to appear identical. The complete sequence and final modifications are necessary to recreate the studied compound. The general term „a peptide composed of six amino acids” does not replace precise identification.

15. Does good tolerance in a small study prove safety?

No. It only describes observations made in a limited group and over a limited observation time. Rare events, prolonged exposure, and populations particularly vulnerable may remain unstudied. Safety conclusions should be proportional to the data, rather than becoming a general assurance for the entire class. A rare adverse event may not occur in a small study, even if the actual risk exists. Longer observation and systematic reporting are needed to formulate broader conclusions.

16. Does the purity certificate confirm its suitability for human use?

No. Purity is one of the analytical characteristics of the tested sample. It does not independently confirm the absence of impurities, stability, proper active substance content, clinical efficacy, or regulatory approval. The certificate does not eliminate the difference between the test material and the verified therapeutic formulation. Chemical identity, purity, activity, microbiological quality, and the suitability of the finished product are separate issues. A single analytical value cannot answer all these questions.

17. What evidence would strengthen the specific claim regarding GHRP?

A controlled study of a well-defined compound and formulation in the target population would be needed. It should measure the declared clinical outcome and systematically assess adverse effects over an appropriate period. Independent replication of the study would then help determine whether the result is reproducible. Such a design would have to distinguish the transient biological signal from the significant clinical effect. Transparent reporting and replication would help determine whether the observation also applies to people outside the primary group.

Interpretation of the studies – from hormonal responses to clinical results

When analyzing the publication regarding GHRP, the first question should be whether the researchers were evaluating GHRP-2, GHRP-6, another analog, or a broader category of substances that stimulate the secretion of growth hormone.

The second question concerns the measured result.

A receptor test can confirm pharmacological activity, a stimulation trial in humans can characterize hormone secretion, and a clinical study can assess a result relevant to the patient.

These are different levels of evidence and should not be presented as confirming the same thing.

A particularly common mistake is to equate a higher peak in growth hormone concentration with better muscle development, regeneration, or healthy aging.

Such inference requires additional stages of evidence that the short-term experiments did not include.

Similarly, pediatric studies involve selected children with low birth weight or growth hormone deficiency, while the mouse study of lung damage refers to an artificially induced disease model.

Each of these results belongs to a separate category of evidence.

Detailed summaries retain these boundaries, even if the observations are of biological interest.

The number of the investigated groups should also be given.

Nine healthy men in the GHRH antagonist experiment, seven men in the appetite study, and 77 healthy participants and 58 patients in the diagnostic study do not constitute comparable populations.

Presenting the number of participants along with endpoints facilitates the assessment of the extent of evidence and reduces the risk of suggesting that the entire class of GHRPs was tested in a single large, uniform clinical program.

Gaps in the studies and questions requiring further evaluation

Future clinical trials should clearly specify the specific GHRP, the validated formulation, and the appropriately justified population.

Next, the researchers should select endpoints that are consistent with the proposed claim.

For example, a study on physical fitness would require direct measurements of functional parameters, whereas a study of a hormonal diagnostic test should assess diagnostic accuracy and reproducibility.

The immediate hormonal response alone does not fully answer any of these questions.

Appropriate control groups, sufficiently long observation periods, and systematic monitoring of adverse events would also be necessary.

Researchers should distinguish the effects related to the molecule itself from problems resulting from the formulation, and report significant changes in hormones other than GH if they are part of the research questions.

Larger, independent studies would be needed to assess rare events and the repeatability of potential clinical benefits.

In scientific databases, the most useful practice is to maintain the exact name of the peptide, the study design, the population, the endpoint, and the regulatory context for each record.

This approach allows for updates to the conclusions as new evidence emerges without transferring results between molecules or indications.

Conclusions

Growth hormone-releasing peptides constitute a pharmacological class with confirmed hormonal activity and a diverse history of research.

GHRP-2 and GHRP-6 should be evaluated separately, keeping the distinction between diagnostic results, physiological responses, and clinical benefits.

The ability to stimulate hormone secretion is evidence of biological activity, but it does not confirm all the effects attributed to this hormone.

Educational, medical and regulatory reservations

The article is of purely scientific and educational nature. It does not constitute medical advice, diagnosis, treatment recommendations, or instructions for the acquisition, preparation, administration, or combination of GHRPs. These compounds can affect several hormonal pathways, and their safety depends on the specific substance, formulation, population, and exposure conditions. Scientific reports and regulatory communications indicate uncertainty regarding adverse events, impurities, aggregation, and immunogenicity. Evaluation of growth disorders or hormonal functions requires consultation with an appropriately qualified specialist.

Regulatory status depends on the country, product, and indication. Japanese documentation regarding the diagnostic use of pramiracetam does not confirm the general approval of GHRP-2, GHRP-6, or other growth hormone secretion-stimulating substances for chronic treatment in Poland or other jurisdictions. Products labeled as intended solely for scientific research are not therefore considered drugs.

References

1. Howard, A. D., Feighner, S. D., Cully, D. F., Arena, J. P., Liberator, P. A., Rosenblum, C. I., Hamelin, M., Hreniuk, D. L., Palyha, O. C., Anderson, J., Paress, P. S., Diaz, C., Chou, M., Liu, K. K., McKee, K. K., Pong, S. S., Chaung, L. Y., Elbrecht, A., Dashkevicz, M., … Van der Ploeg, L. H. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science (New York, N.Y.), 273(5277), 974–977. https://doi.org/10.1126/science.273.5277.974
2. Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from the stomach. Nature, 402(6762), 656–660. https://doi.org/10.1038/45230
3. Pharmaceuticals and Medical Devices Agency. (2004). Pralmorelin hydrochloride / GHRP Kaken 100: Review report [Japanese regulatory assessment; descriptive English title]. https://www.pmda.go.jp/drugs/2004/P200400019/20002200_21600AMZ00572_Q100_1.pdf
4. Pandya, N., DeMott-Friberg, R., Bowers, C. Y., Barkan, A. L., & Jaffe, C. A. (1998). Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. The Journal of clinical endocrinology and metabolism, 83(4), 1186–1189. https://doi.org/10.1210/jcem.83.4.4711
5. Peñalva, A., Pombo, M., Carballo, A., Barreiro, J., Casanueva, F. F., & Dieguez, C. (1993). Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6. Clinical endocrinology, 38(1), 87–91. https://doi.org/10.1111/j.1365-2265.1993.tb00977.x
6. Arvat, E., di Vito, L., Maccagno, B., Broglio, F., Boghen, M. F., Deghenghi, R., Camanni, F., & Ghigo, E. (1997). Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides, 18(6), 885–891. https://doi.org/10.1016/s0196-9781(97)00016-8
7. Chihara, K., Shimatsu, A., Hizuka, N., Tanaka, T., Seino, Y., Katofor, Y., & KP-102 Study Group. (2007). A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. European journal of endocrinology, 157(1), 19–27. https://doi.org/10.1530/EJE-07-0066
8. Laferrère, B., Abraham, C., Russell, C. D., & Bowers, C. Y. (2005). Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. The Journal of clinical endocrinology and metabolism, 90(2), 611–614. https://doi.org/10.1210/jc.2004-1719
9. Pihoker, C., Badger, T. M., Reynolds, G. A., & Bowers, C. Y. (1997). Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. The Journal of endocrinology, 155(1), 79–86. https://doi.org/10.1677/joe.0.1550079
10. Mericq, V., Cassorla, F., Salazar, T., Avila, A., Iñiguez, G., Bowers, C. Y., & Merriam, G. R. (1998). Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. The Journal of clinical endocrinology and metabolism, 83(7), 2355–2360. https://doi.org/10.1210/jcem.83.7.4969
11. Wang, L., Berlanga-Acosta, J., Yu, H., García-Ojalvo, A., Jiang, T., Li, N., Zhang, Z., Guillén-Nieto, G., & Jiang, B. (2026). Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolution to interstitial fibrosis. International immunopharmacology, 172, 116204. https://doi.org/10.1016/j.intimp.2026.116204
12. U.S. Food and Drug Administration. (n.d.). Certain bulk drug substances for use in compounding that may present significant safety risks. Retrieved October 23, 2026, from https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks